Does the media refer more to NTLA or TECX?

In the previous week, Intellia Therapeutics had 8 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 11 mentions for Intellia Therapeutics and 3 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.95 beat Intellia Therapeutics' score of 0.69 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GENB or TECX more profitable?

Generate Biomedicines' return on equity of 0.00% beat Tectonic Therapeutic's return on equity. Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A Tectonic Therapeutic N/A -35.26% -33.59%

Does the media refer more to GENB or TECX?

In the previous week, Generate Biomedicines had 5 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 8 mentions for Generate Biomedicines and 3 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.95 beat Generate Biomedicines' score of 0.47 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tectonic Therapeutic 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SEPN or TECX?

In the previous week, Septerna and Septerna both had 3 articles in the media. Septerna's average media sentiment score of 1.09 beat Tectonic Therapeutic's score of 0.95 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TECX or NUVB?

In the previous week, Tectonic Therapeutic and Tectonic Therapeutic both had 3 articles in the media. Tectonic Therapeutic's average media sentiment score of 0.95 beat Nuvation Bio's score of -0.18 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvation Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer STOK or TECX?

In the previous week, Stoke Therapeutics had 3 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 6 mentions for Stoke Therapeutics and 3 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.95 beat Stoke Therapeutics' score of 0.54 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tectonic Therapeutic (TECX) Competitors

$20.68 -0.63 (-2.93%)

As of 12:47 PM Eastern

Compare

TECX vs. NTLA, GENB, SEPN, NUVB, and STOK

Should you buy Tectonic Therapeutic stock or one of its competitors? Tectonic Therapeutic's main competitors and comparable companies include Intellia Therapeutics (NTLA), Generate Biomedicines (GENB), Septerna (SEPN), Nuvation Bio (NUVB), and Stoke Therapeutics (STOK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tectonic Therapeutic compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Intellia Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.28, indicating that its stock price is 228% more volatile than the broader market.

Tectonic Therapeutic has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Tectonic Therapeutic's return on equity of -35.26% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

Intellia Therapeutics presently has a consensus price target of $20.72, suggesting a potential upside of 73.95%. Tectonic Therapeutic has a consensus price target of $69.17, suggesting a potential upside of 224.57%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts plainly believe Tectonic Therapeutic is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	5 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.26
Tectonic Therapeutic	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80

In the previous week, Intellia Therapeutics had 8 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 11 mentions for Intellia Therapeutics and 3 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.95 beat Intellia Therapeutics' score of 0.69 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tectonic Therapeutic has lower revenue, but higher earnings than Intellia Therapeutics. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	24.66	-$412.69M	-$3.36	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Tectonic Therapeutic beats Intellia Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Generate Biomedicines?

Generate Biomedicines (NASDAQ:GENB) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

62.6% of Tectonic Therapeutic shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Generate Biomedicines had 5 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 8 mentions for Generate Biomedicines and 3 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.95 beat Generate Biomedicines' score of 0.47 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tectonic Therapeutic	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Generate Biomedicines currently has a consensus target price of $26.40, suggesting a potential upside of 115.33%. Tectonic Therapeutic has a consensus target price of $69.17, suggesting a potential upside of 224.57%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Tectonic Therapeutic	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80

Tectonic Therapeutic has lower revenue, but higher earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$31.89M	49.34	-$203.15M	-$1.59	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

Generate Biomedicines' return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Tectonic Therapeutic	N/A	-35.26%	-33.59%

Summary

Tectonic Therapeutic beats Generate Biomedicines on 7 of the 13 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Septerna?

Septerna (NASDAQ:SEPN) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

62.6% of Tectonic Therapeutic shares are owned by institutional investors. 5.8% of Septerna shares are owned by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Tectonic Therapeutic has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.57%	-6.28%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

In the previous week, Septerna and Septerna both had 3 articles in the media. Septerna's average media sentiment score of 1.09 beat Tectonic Therapeutic's score of 0.95 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.28, suggesting that its stock price is 228% more volatile than the broader market.

Septerna has higher revenue and earnings than Tectonic Therapeutic. Septerna is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	37.00	-$48.88M	-$0.54	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

Septerna currently has a consensus price target of $52.44, indicating a potential upside of 44.00%. Tectonic Therapeutic has a consensus price target of $69.17, indicating a potential upside of 224.57%. Given Tectonic Therapeutic's higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Tectonic Therapeutic	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80

Summary

Septerna beats Tectonic Therapeutic on 8 of the 15 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Nuvation Bio?

Tectonic Therapeutic (NASDAQ:TECX) and Nuvation Bio (NYSE:NUVB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

In the previous week, Tectonic Therapeutic and Tectonic Therapeutic both had 3 articles in the media. Tectonic Therapeutic's average media sentiment score of 0.95 beat Nuvation Bio's score of -0.18 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tectonic Therapeutic has a beta of 3.28, meaning that its stock price is 228% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

Tectonic Therapeutic has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
Nuvation Bio	$62.90M	26.38	-$204.63M	-$0.44	N/A

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tectonic Therapeutic currently has a consensus price target of $69.17, suggesting a potential upside of 224.57%. Nuvation Bio has a consensus price target of $13.22, suggesting a potential upside of 179.84%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Tectonic Therapeutic has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Tectonic Therapeutic's return on equity of -35.26% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.26%	-33.59%
Nuvation Bio	-88.18%	-46.59%	-22.01%

Summary

Tectonic Therapeutic beats Nuvation Bio on 11 of the 15 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Tectonic Therapeutic has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Tectonic Therapeutic's return on equity of -35.26% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

62.6% of Tectonic Therapeutic shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Stoke Therapeutics had 3 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 6 mentions for Stoke Therapeutics and 3 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.95 beat Stoke Therapeutics' score of 0.54 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stoke Therapeutics presently has a consensus price target of $44.25, indicating a potential upside of 96.67%. Tectonic Therapeutic has a consensus price target of $69.17, indicating a potential upside of 224.57%. Given Tectonic Therapeutic's higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Tectonic Therapeutic	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80

Stoke Therapeutics has higher revenue and earnings than Tectonic Therapeutic. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	7.87	-$6.89M	-$3.34	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

Stoke Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.28, suggesting that its stock price is 228% more volatile than the broader market.

Summary

Tectonic Therapeutic beats Stoke Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Tectonic Therapeutic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TECX vs. The Competition

Export

Metric	Tectonic Therapeutic	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$404.78M	$3.89B	$7.28B	$13.01B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-4.53	12.99	275.44	25.42
Price / Sales	N/A	1,141.69	559.80	78.81
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	1.54	16.88	10.66	5.96
Net Income	-$74.15M	-$22.65M	$3.50B	$380.62M
7 Day Performance	-8.91%	-5.64%	-3.65%	-3.75%
1 Month Performance	-30.37%	-13.53%	-8.06%	-6.62%
1 Year Performance	28.56%	6.87%	2.58%	-4.38%

Tectonic Therapeutic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TECX Tectonic Therapeutic	2.9003 of 5 stars	$20.69 -2.9%	$69.17 +234.4%	+32.4%	$404.78M	N/A	N/A	60	Analyst Upgrade
NTLA Intellia Therapeutics	3.3296 of 5 stars	$12.37 -3.0%	$20.72 +67.5%	-49.9%	$1.79B	$67.67M	N/A	377	Gap Up
GENB Generate Biomedicines	2.2565 of 5 stars	$13.80 -0.8%	$26.40 +91.3%	N/A	$1.79B	$31.89M	N/A	312	News Coverage Gap Up
SEPN Septerna	2.55 of 5 stars	$35.67 -5.8%	$52.44 +47.0%	+51.2%	$1.77B	$45.95M	N/A	130
NUVB Nuvation Bio	2.317 of 5 stars	$4.86 -1.7%	$13.22 +171.8%	+28.2%	$1.74B	$62.90M	N/A	305

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TECX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tectonic Therapeutic (TECX) Competitors

TECX vs. NTLA, GENB, SEPN, NUVB, and STOK

How does Tectonic Therapeutic compare to Intellia Therapeutics?

Summary

How does Tectonic Therapeutic compare to Generate Biomedicines?

Summary

How does Tectonic Therapeutic compare to Septerna?

Summary

How does Tectonic Therapeutic compare to Nuvation Bio?

Summary

How does Tectonic Therapeutic compare to Stoke Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX vs. The Competition

Tectonic Therapeutic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tectonic Therapeutic (TECX) Competitors

TECX vs. NTLA, GENB, SEPN, NUVB, and STOK

How does Tectonic Therapeutic compare to Intellia Therapeutics?

Which has more volatility and risk, NTLA or TECX?

Is NTLA or TECX more profitable?

Do analysts rate NTLA or TECX?

Does the media refer more to NTLA or TECX?

Which has higher valuation and earnings, NTLA or TECX?

Do institutionals & insiders have more ownership in NTLA or TECX?

Summary

How does Tectonic Therapeutic compare to Generate Biomedicines?

Do insiders & institutionals have more ownership in GENB or TECX?

Does the media refer more to GENB or TECX?

Do analysts rate GENB or TECX?

Which has preferable earnings & valuation, GENB or TECX?

Is GENB or TECX more profitable?

Summary

How does Tectonic Therapeutic compare to Septerna?

Do insiders and institutionals have more ownership in SEPN or TECX?

Is SEPN or TECX more profitable?

Does the media refer more to SEPN or TECX?

Which has more risk & volatility, SEPN or TECX?

Which has preferable valuation and earnings, SEPN or TECX?

Do analysts recommend SEPN or TECX?

Summary

How does Tectonic Therapeutic compare to Nuvation Bio?

Does the media favor TECX or NUVB?

Which has more risk & volatility, TECX or NUVB?

Which has stronger valuation & earnings, TECX or NUVB?

Do institutionals and insiders hold more shares of TECX or NUVB?

Do analysts rate TECX or NUVB?

Is TECX or NUVB more profitable?

Summary

How does Tectonic Therapeutic compare to Stoke Therapeutics?

Is STOK or TECX more profitable?

Do institutionals & insiders believe in STOK or TECX?

Does the media prefer STOK or TECX?

Do analysts prefer STOK or TECX?

Which has preferable valuation & earnings, STOK or TECX?

Which has more volatility & risk, STOK or TECX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX vs. The Competition

Tectonic Therapeutic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools